New paradigms and tools in drug design for pain and addiction

AAPS Journal

Volumn 8, Issue 3, 2006, Pages

  Hruby, Victor J ^a   Porreca, Frank ^b   Yamamura, Henry I ^b   Tollin, Gordon ^a   Agnes, Richard S ^a   Lee, Yeon Sun ^a   Cai, Minying ^a   Alves, Isabel ^a   Cowell, Scott ^a   Varga, Eva ^b   Davis, Peg ^b   Salamon, Zdzislaw ^a   Roeske, William ^b   Vanderah, Todd ^b   Lai, Josephine ^b  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Bifunctional ligands; Cholecyctokinin receptors; Drug design; GPCRs; Neuropathic pain; Opioid receptors; Plasmon waveguide resonance spectroscopy

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANALGESIC AGENT; CHOLECYSTOKININ DERIVATIVE; CHOLECYSTOKININ RECEPTOR; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DRUGS USED IN THE TREATMENT OF ADDICTION; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; G PROTEIN COUPLED RECEPTOR; LIGAND; MORPHINE; MU OPIATE RECEPTOR; NALTRINDOLE; OPIATE AGONIST; OPIATE ANTAGONIST; RSA 601; SNF 9007; UNCLASSIFIED DRUG;

ADDICTION; CHEMICAL MODIFICATION; COMBINATORIAL CHEMISTRY; DRUG DESIGN; DRUG DETERMINATION; DRUG MECHANISM; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; NEUROPATHIC PAIN; NONHUMAN; PAIN; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; RECEPTOR AFFINITY; RECEPTOR BLOCKING; REVIEW; SPECTROSCOPY; STRUCTURE ACTIVITY RELATION;

BEHAVIOR, ADDICTIVE; DRUG DESIGN; OPIOID PEPTIDES; PAIN; PAIN CLINICS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746446373     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/aapsj080353     Document Type: Review

References (30)

1. Hruby VJ. Designing peptide receptor agonists and antagonists. Nat Rev Drug Discov, 2002;1:847-858.
2. Ossipov MH, Lai J, Porreca F. Mechanisms of experimental neuropathic pain: Integration from animal models. In: McMahon S, Koltzenburg M, eds. Wall and Melzack's Textbook of Pain. 5th ed. New York, NY: Elsevier; 2005:929-946.
3. Ossipov MH, Porreca F. Challenges in the development of novel treatment strategies for neuropathic pain. NeuroRx. 2005;2:650-661.
4. Vera-Portocarrero LP, Zhang ET, Ossipov MH, et al. Descending facilitation from the rostral ventromedial medulla maintains nerve injury-induced central sensitization. Neuroscience. In press.
5. Ossipov MH, Porreca F. Descending modulation of pain. In: Merskey H, Loeser JD, Dubner R, eds. The Paths of Pain 1975-2005. Seattle, WA: IASP Press; 2005:117-130.
6. Xie JY, Herman SD, Stiller CO, et al. Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance. J Neurosci. 2005;25:409-416.
7. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals. 2005;14:194-205.
8. Heinricher MM, Neubert MJ. Neural basis for the hyperalgesic action of cholecystokinin in the rostral ventromedial medulla. J Neurophysiol. 2004;92:1982-1989.
9. Wilcox GL, Stone LS, Ossipov MH, Lai J, Porreca F. Pharmacology of pain and analgesia. In: Pappagallo M, ed. The Neurologic Basis of Pain. New York, NY: McGraw-Hill; 2004:31-52.
10. Hruby VJ, Meyer J-P. Chemical synthesis of peptides. In: Hecht SM, ed. Bioorganic Chemistry: Peptides and Proteins. New York, NY: Oxford University Press; 1998:27-64.
11. Misicka A, Lipkowski AW, Horvath R, et al. Topographical requirements for δ opioid ligands: common structural features of dermenkephalin and deltorphin. Life Sci. 1992;51:1025-1032.
12. Kramer TH, Davis P, Hruby VJ, Burks TF, Porreca F. In vitro potency, affinity and agonist efficacy of highly selective δ opioid receptor ligands. J Pharmacol Exp Ther. 1993;266:577-584.
13. Salamon Z, Macleod HA, Tollin G. Coupled plasmon-waveguide resonators: a new spectroscopic tool for probing proteolipid film structure and properties. Biophys J. 1997;73:2791-2797.
14. Salamon Z, Tollin G. Plasmon resonance spectroscopy: probing molecular interactions at surfaces and interfaces. Spectroscopy. 2005;15:161-175.
15. Tollin G, Salamon Z, Hruby VJ. Techniques: plasmon-waveguide resonance (PWR) spectroscopy as a tool to study ligand-GPCR interactions. Trends Pharmacol Sci. 2003;24:655-659.
16. Salamon Z, Cowell S, Varga E, Yamamura HI, Hruby VJ, Tollin G. Plasmon resonance studies of agonist/antagonist binding to the human δ-opioid receptor: new structural insights into receptor-ligand interactions. Biophys J. 2000;79:2463-2474.
17. Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, Hruby VJ. Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem. 2003;278:48890-48897.
18. Slaninová J, Knapp RJ, Wu J, et al. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur J Pharmacol. 1991;200:195-198.
19. Mosberg HI, Hurst R, Hruby VJ, et al. Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors. Proc Natl Acad Sci USA. 1983;80:5871-5874.
20. 26-33 selective for B-type CCK receptors possess δ opioid receptor agonist activity in vitro and in vivo: Evidence for similarities in CCK-B and δ opioid receptor requirements. In: Hodges RS, Smith JA, eds. Peptides: Chemistry, Structure and Biology. Proceedings of the 13th American Peptide Symposium; June 20-25, 1993; Alberta, Canada. Leiden, The Netherlands: ESCOM Publishers; 1994:669-671.
21. Nikiforovich GV, Hruby VJ, Prakash O, Gehrig CA. Topographical requirements for δ-selective opioid peptides. Biopolymers. 1991;31:941-955.
22. Hruby VJ, Fang SN, Knapp R, Kazmierski WM, Lui GK, Yamamura HI. Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors. Int J Pept Protein Res. 1990;35:566-573.
23. Hruby VJ. Conformational restrictions of biologically active peptides via amino acid side chain groups. Life Sci. 1982;31:189-199.
24. Hruby VJ, Al-Obeidi F, Kazmierski WM. Emerging approaches in the molecular design of receptor selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J. 1990;268:249-262.
25. Bartosz-Bechowski H, Davis P, Slaninova J, et al. Cyclic enkephalin analogues that are hybrids of DPDPE-related peptides and Met-enkephalin-Arg-Gly-Leu: prohormone analogues that retain good potency and selectivity for δ opioid receptors. J Pept Res. 1999;53:329-336.
26. Hruby VJ, Bartosz-Bechowski H, Davis P, et al. Cyclic enkephalin analogues with exceptional potency and selectivity for δ-opioid receptors. J Med Chem. 1997;40:3957-3962.
27. Alves ID, Cowell SM, Salamon Z, Devanathan S, Tollin G, Hruby VJ. Different structural states of the proteolipid membrane are produced by ligand binding to the human δ-opioid receptor as shown by plasmon-waveguide resonance spectroscopy. Mol Pharmacol. 2004;65:1248-1257.
28. Hosohata Y, Varga EV, Stropova D, et al. Mutation W284L of the human δ opioid receptor reveals agonist specific conformational mechanisms of G-protein activation. Life Sci. 2001;68:2233-2242.
29. Alves ID, Salamon Z, Varga E, Yamamura HI, Tollin G, Hruby VJ. Direct observation of G-protein binding to the human δ-opioid receptor using plasmon-waveguide resonance spectroscopy. J Biol Chem. 2003;278:48890-48897.
30. Alves ID, Ciano KA, Boguslavsky V, et al. Selectivity, cooperativity, and reciprocity in the interactions between the δ-opioid receptor, its ligands, and G-proteins. J Biol Chem. 2004;279:44673-44682.